As Merck buyout buzz heats up, Seagen touts a positive update on their Padcev/Keytruda combo
Most of the news at Seagen these days revolves around hot buzz about a potential $40 billion-plus Merck buyout. But today the focus has shifted to an experimental combo that uses the pharma giant’s big PD-1 cancer drug Keytruda.
Execs at Seagen and their partner Astellas posted positive top-line numbers for a combination of Padcev and Keytruda, noting a confirmed overall response rate of 64.5% for frontline urothelial cancer patients who are ineligible for cisplatin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.